Company intelligence / Profile preview
Receptor Life Sciences
- Ownership
- Private
- Development stage
- Phase 1
Overview
Receptor Life Sciences has advanced its lead candidate, RLS103—an inhaled dry powder cannabidiol (CBD) formulation—into clinical trials targeting acute psychiatric and neurological disorders. The company recently secured $9.7 million in Series A1 financing to support these efforts. The IND for RLS103 has been accepted by the FDA, with first-in-human studies initiated. The product aims to address significant unmet needs in acute anxiety treatment with a rapid-onset cannabinoid therapy delivered via inhalation.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (cannabinoids)Drug/device combination products (inhaled and oral formulations)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Receptor Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Receptor Life Sciences.